Pyxis Oncology (PYXS) Earnings Analysis
Pyxis Oncology (PYXS) next reports earnings on 2026-08-13, consensus EPS -0.34 USD. Last quarter (2026-05-14) it missed with EPS -0.37 USD vs -0.35 USD est (-5.7%). It has beaten estimates in 5/7 recent quarters (71%). Trailing P/E -1.93.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does PYXS next report earnings?
| Next earnings date | 2026-08-13 |
|---|---|
| Consensus EPS estimate | -0.34 USD |
| Revenue estimate | 0.00B |
PYXS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-14 | -0.37 USD | -0.35 USD | -5.7% | Miss |
| 2026-03-23 | -0.29 USD | -0.35 USD | +17.1% | Beat |
| 2025-11-03 | -0.35 USD | -0.36 USD | +2.8% | Beat |
| 2025-08-14 | -0.3 USD | -0.36 USD | +16.7% | Beat |
| 2025-05-15 | -0.35 USD | -0.29 USD | -20.7% | Miss |
| 2025-03-18 | -0.32 USD | -0.33 USD | +3% | Beat |
| 2024-08-14 | -0.29 USD | -0.33 USD | +12.1% | Beat |
Beat rate: 5/7 (71%) over reported quarters with consensus data.
PYXS valuation and analyst view
| Trailing P/E | -1.93 |
|---|---|
| Trailing EPS | -1.28778 USD |
| Price / book | 5.14 |
| Dividend yield | 0.00% |
| Market cap | 0.14B |
| Analyst consensus | Buy (8 buy / 2 hold / 0 sell) |
| Avg price target | 6.5 USD |
Related research pages
Frequently asked questions
When is Pyxis Oncology (PYXS)'s next earnings date?
Pyxis Oncology is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.34 USD and revenue estimate of 0.00B.
Did PYXS beat earnings last quarter?
In its 2026-05-14 report, PYXS posted EPS of -0.37 USD versus a -0.35 USD estimate — a miss of 5.7%.
What is PYXS's earnings track record?
Over the last 7 reported quarters with consensus data, PYXS beat estimates 5 times (71%).
What is PYXS's current P/E ratio and EPS?
PYXS trades at a trailing P/E of -1.93 on trailing EPS of -1.2877767948088739 USD.
What do analysts rate PYXS?
Analyst consensus is "Buy" across 10 ratings (0 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 6.5 USD.